Literature DB >> 16400259

Treatment of Alzheimer's disease: current and future therapeutic approaches.

Jeffrey L Cummings1.   

Abstract

The pathophysiology of Alzheimer's disease (AD) includes the deposition of amyloid beta protein (Abeta) and the ensuing initiation of a variety of secondary processes, including tau hyperphosphorylation, excitotoxicity, oxidation, and inflammation. Nerve cell loss in structures responsible for manufacturing neurotransmitters results in a variety of neurochemical deficits. Current therapeutic approaches to the treatment of AD include cholinesterase inhibitors for mild to moderate disease, memantine for moderate to severe disease, and vitamin E or selegiline. Reduction of Abeta generation or aggregation, enhancement of Abeta removal, interruption of tau hyperphosphorylation, and the use of more efficacious antioxidant or anti-inflammatory agents represent promising therapeutic strategies currently being investigated. Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16400259

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN: 1545-2913


  32 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 2.  Neuroethics: a modern context for ethics in neuroscience.

Authors:  Judy Illes; Stephanie J Bird
Journal:  Trends Neurosci       Date:  2006-07-21       Impact factor: 13.837

3.  Curing and caring: the work of primary care physicians with dementia patients.

Authors:  Ester Carolina Apesoa-Varano; Judith C Barker; Ladson Hinton
Journal:  Qual Health Res       Date:  2011-06-17

4.  Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.

Authors:  Alessandra S Kiametis; Mônica A Silva; Luiz A S Romeiro; João B L Martins; Ricardo Gargano
Journal:  J Mol Model       Date:  2017-02-09       Impact factor: 1.810

5.  Chronic Physical Conditions, Multimorbidity, and Mild Cognitive Impairment in Low- and Middle-Income Countries.

Authors:  Ai Koyanagi; Elvira Lara; Brendon Stubbs; Andre F Carvalho; Hans Oh; Andrew Stickley; Nicola Veronese; Davy Vancampfort
Journal:  J Am Geriatr Soc       Date:  2018-02-10       Impact factor: 5.562

6.  Eugenol Attenuates Scopolamine-Induced Hippocampal Cholinergic, Glutamatergic, and Mitochondrial Toxicity in Experimental Rats.

Authors:  Debapriya Garabadu; Mahima Sharma
Journal:  Neurotox Res       Date:  2019-02-09       Impact factor: 3.911

7.  Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological investigation.

Authors:  Stefania Butini; Margherita Brindisi; Simone Brogi; Samuele Maramai; Egeria Guarino; Alessandro Panico; Ashima Saxena; Ved Chauhan; Raffaella Colombo; Laura Verga; Ersilia De Lorenzi; Manuela Bartolini; Vincenza Andrisano; Ettore Novellino; Giuseppe Campiani; Sandra Gemma
Journal:  ACS Med Chem Lett       Date:  2013-10-06       Impact factor: 4.345

Review 8.  A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.

Authors:  Aida Adlimoghaddam; Melanie Neuendorff; Banibrata Roy; Benedict C Albensi
Journal:  CNS Neurosci Ther       Date:  2018-07-29       Impact factor: 5.243

9.  Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.

Authors:  Jacqueline Hofrichter; Markus Krohn; Toni Schumacher; Cathleen Lange; Björn Feistel; Bernd Walbroel; Hans-Jochen Heinze; Sara Crockett; Timothy F Sharbel; Jens Pahnke
Journal:  Curr Alzheimer Res       Date:  2013-12       Impact factor: 3.498

10.  "Thinking about it for somebody else": Alzheimer's disease research and proxy decision makers' translation of ethical principles into practice.

Authors:  Laura B Dunn; Stephanie Reyes Fisher; Melinda Hantke; Paul S Appelbaum; Daniel Dohan; Jenifer P Young; Laura Weiss Roberts
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.